Sphingosine-1-Phosphate Receptor Agonist Fingolimod Increases Myocardial Salvage and Decreases Adverse Postinfarction Left Ventricular Remodeling in a Porcine Model of Ischemia/Reperfusion | Zendy

Carlos G. SantosGallego | Zendy; Torsten Vahl | Zendy; Georg Goliasch | Zendy; Belén Picatoste | Zendy; Teresa Arias | Zendy; Kiyotake Ishikawa | Zendy; Ida U Njerve | Zendy; Javier Sanz | Zendy; Jagat Narula | Zendy; Partho P. Sengupta | Zendy; Roger J. Hajjar | Zendy; Valentı́n Fuster | Zendy; Juan J. Badimón | Zendy

Open Access

Sphingosine-1-Phosphate Receptor Agonist Fingolimod Increases Myocardial Salvage and Decreases Adverse Postinfarction Left Ventricular Remodeling in a Porcine Model of Ischemia/Reperfusion

Author(s) -

Carlos G. SantosGallego,

Torsten Vahl,

Georg Goliasch,

Belén Picatoste,

Teresa Arias,

Kiyotake Ishikawa,

Ida U Njerve,

Javier Sanz,

Jagat Narula,

Partho P. Sengupta,

Roger J. Hajjar,

Valentı́n Fuster,

Juan J. Badimón

Publication year - 2016

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.115.012427

Subject(s) - fingolimod , medicine , cardioprotection , ventricular remodeling , cardiology , reperfusion injury , reperfusion therapy , myocardial infarction , sphingosine kinase , agonist , pharmacology , ischemia , sphingosine , sphingosine 1 phosphate , receptor , immunology , multiple sclerosis

Fingolimod, a sphingosine-1-phosphate receptor agonist, is used for the treatment of multiple sclerosis and exerts antiapoptotic properties. We hypothesized that sphingosine-1-phosphate receptor activation with fingolimod during acute myocardial infarction (MI) inhibits apoptosis, leading to increased myocardial salvage, reduced infarct size, and mitigated left ventricular (LV) remodeling in a porcine model of ischemia/reperfusion.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research